SuperGen to Present at BIO Investor Forum on October 29, 2009

DUBLIN, Calif.--(BUSINESS WIRE)--SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., President and Chief Executive Officer, will present at the 8^th Annual BIO Investor Forum on October 29, 2009 in San Francisco.

SuperGen's presentation will begin at 9:30 a.m. PT. A live webcast of the presentation will be available on the investor relations section of the Company's Web site at www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit http://www.supergen.com.

Contacts

Timothy L. Enns
SuperGen, Inc.
Senior Vice President,
Corporate Communications & Business Development
Tel: (925) 560-2810
E-mail: tenns@supergen.com
or
Susanna Chau
SuperGen, Inc.
Manager,
Investor Relations
Tel: (925) 560-2845
E-mail: schau@supergen.com

Recent Stories from SuperGen, Inc.

FDA’s Oncologic Drugs Advisory Committee (ODAC) Votes to not Support Benefit/Risk Profile of DACOGEN® (decitabine) in Acute Myeloid Leukemia

February 09, 2012

DUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) today announced that the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) voted 10 to... more »
Astex Pharmaceuticals Announces Presentations at Upcoming Conferences

February 06, 2012

DUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced... more »
Astex Announces Early Transfer of Epigenetics Project to GSK

January 16, 2012

DUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) today announced that the multi-year collaboration to discover cancer therapeutics based on epigenetic targets entered int... more »